Tumor necrosis factor mediates the impact of PM2.5 on bone mineral density: Inflammatory proteome Mendelian

Mingzheng Li1, Peng Shi1, Huajie Yang1

  • 1Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention (China Medical University), Ministry of Education, China; Department of Environmental and Occupational Health, School of Public Health, China Medical University, Shenyang 110122, China.

Insights

Exposure to fine particulate matter (PM2.5) negatively impacts bone mineral density (BMD), with this effect mediated by tumor necrosis factor (TNF). Targeting TNF or its receptor (TNFR1) may offer a promising strategy for preventing osteoporosis (OP).

Area of Science:

  • Environmental Health Sciences
  • Genetics
  • Rheumatology

Background:

  • Particulate matter 2.5 (PM2.5) exposure is a global concern.
  • Its impact on bone mineral density (BMD) and the underlying mechanisms require elucidation.
  • Inflammation-associated proteins may play a role in PM2.5-induced bone loss.

Purpose of the Study:

  • To determine the causal effect of PM2.5 on BMD.
  • To investigate the mediating role of inflammation-related proteins, specifically tumor necrosis factor (TNF) and protachykinin-1 (TAC-1).
  • To explore the potential of TNF inhibitors for osteoporosis (OP) prevention.

Main Methods:

  • Two-sample Mendelian randomization (TSMR) and multivariate Mendelian randomization (MVMR) were employed.
  • Linkage Disequilibrium Score (LDSC) assessed genetic correlation.
  • Bayesian colocalization and drug-target MR analyses were utilized.

Main Results:

  • PM2.5 showed a negative causal association with BMD (β = -0.288).
  • PM2.5 causally influenced TNF (β = 1.564) and TAC-1 (β = -1.654).
  • TNF mediated the association between PM2.5 and BMD; TAC-1 did not.
  • TNF inhibition demonstrated a protective effect on BMD, suggesting TNFR1 as a potential therapeutic target for OP.

Conclusions:

  • PM2.5 exposure causally reduces BMD.
  • The observed effect is significantly mediated by TNF.
  • Targeting TNF/TNFR1 presents a viable therapeutic avenue for osteoporosis prevention.